CGM

By Jonah Comstock September 27, 2017
Abbott Diabetes Care's Freestyle Libre Flash Glucose Monitoring System has been approved by the FDA. As well as finally bringing the system, which is already available in 39 other countries, home to the US where Abbott is based, the approval also represents a first for continuous glucose monitoring, as it doesn't require the user to use a fingerstick, even for calibration. "From an emotional...
By Jonah Comstock September 7, 2017
Good news for anyone who thought Fitbit's move toward the smartwatch market would be a move away from health: The wearable maker has just announced a partnership with Dexcom that will bring data from the company's continuous glucose monitor directly to the display of Fitbit's upcoming Ionic smartwatch. Athough Fitbit's have been used in the management of chronic diseases in a number of hospital...
By Jonah Comstock August 21, 2017
A new study published today in Annals of Internal Medicine and sponsored by Dexcom shows that a continuous glucose monitor could lower the HbA1c scores of people with Type 2 diabetes, and that acceptance of the technology is high among that group as well. Right now, continuous glucose monitoring is a technology mostly used by people with Type 1 diabetes, many of whom administer insulin via an...
By Jonah Comstock August 3, 2017
DexCom hasn’t been shy about its plan for opening up the CGM market by encouraging CGM use in a wider group of people with diabetes — including, eventually, people with Type 2 diabetes. On its second quarter earnings call, the company went deep on that focus on the future. “More and more people with diabetes are adopting CGM that as the primary tool to manage their condition, especially as we...
By Jonah Comstock June 7, 2017
At long last, Dexcom's Share app, which allows users to view and share data from their G5 continuous glucose monitors, will be available for Android users. The Android app just now received FDA clearance, and the company will roll out the app this month. The launch is a long time coming: iOS users have had access to the app since 2015. “Providing Android users with access to the Dexcom G5 Mobile...
By Jonah Comstock April 13, 2017
Apple has even more secret health aspirations than anyone realized, according to reporting by Christina Farr for CNBC yesterday. Citing sources inside the company, Farr reports that Apple has a small offsite team dedicated to diabetes research that's been working for about five years. The goal is one many other tech companies are working on but no one's close to cracking: noninvasive, continuous...
By Jonah Comstock March 24, 2017
In January, the Centers for Medicare and Medicaid Services announced that it would cover continuous glucose monitoring for the first time; specifically it would cover therapeutic CGMs, of which the only one currently recognized is the Dexcom G5. That coverage officially kicks in today, now that CMS has issued the billing codes providers can use to get reimbursed. “This is a new era and a huge win...
By Jonah Comstock March 3, 2017
Implantable longterm continuous glucose monitor company Senseonics is in a better place than its financials would suggest. The company posted a net loss of $9.9 million last quarter, up from an $8.4 million loss in the year prior, and is planning to borrow about $5 million from the Oxford Silicon Valley Bank that it’s already $20 million in debt to. But Senseonic’s potentially game-changing...
By Jonah Comstock March 1, 2017
After the latest in a series of successful quarters (with $171.2 million in revenue, up 31 percent year over year), DexCom is queuing up some big product launches. On yesterday’s Q4 earnings call, CEO Kevin Sayer provided more detail about the forthcoming G6 continuous glucose monitor as well as the first products to come out of DexCom’s partnership with Verily. “In a year of much confusion and...
By Jonah Comstock February 15, 2017
GluSense, an Israeli medical device company, announced an undisclosed investment from the JDRF T1D Fund, a recently launched VC philanthropy fund dedicated to funding early stage programs for Type 1 diabetes. GluSense is being incubated in the Rainbow Medical innovation house, a private investment company that seeds and grows medical device companies. The company’s first product in development is...